Unfair Competition in Emerging Health Markets: Reconstructing Competition Law Principles for the Nutraceutical and Biotechnology Sectors

The exponential growth of nutraceutical and biotechnology markets has generated novel forms of competitive conduct that challenge the conceptual foundations of traditional competition law. Positioned between pharmaceuticals and conventional consumer goods, emerging health markets are characterized by regulatory asymmetry, science-driven product differentiation, intellectual property concentration, vertically integrated supply chains, and certification-based market barriers. While classical doctrines of abuse of dominance, anti-competitive agreements, and predatory pricing remain formally applicable, their analytical frameworks were developed in industrial contexts where price and output effects constituted primary indicators of competitive harm. In contrast, competition in nutraceutical and biotechnology sectors frequently manifests through control over scientific validation, health-claim narratives, patent clustering, exclusive sourcing of bio-resources, and regulatory arbitrage. This article argues that emerging health markets expose structural blind spots in existing competition law jurisprudence and require doctrinal reconstruction. Through doctrinal and comparative analysis, the paper identifies typologies of unfair competition unique to these sectors and proposes an expanded analytical model that integrates intellectual property dynamics, regulatory coordination, and non-price competitive indicators. The study contributes to contemporary debates on the evolution of competition law in knowledge-intensive, health-driven economies.